Sign inJoin waitlistJoin the waitlist

SF

Suzanne Fanning

Associate Professor · University of South Carolina-Columbia

Credentials: · · · ·

History

University of South Carolina-Columbia
Present

Hematology and Medical Oncology
2004–2007
Internal Medicine
2001–2004
Philadelphia College of Osteopathic Medicine
1997–2001

Research

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Nature Medicine · 1996 · 2,886 citations
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation…
The Lancet Oncology · 2022 · 223 citations
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A…
Transplantation and Cellular Therapy · 2021 · 172 citations

Daanish Hoda
4 papers
James Essell
4 papers
BS
Bipin Savani
3 papers
Laura Johnston
3 papers
MP
Miguel-Angel Perales
3 papers
Paul Carpenter
3 papers
YI
Yoshihiro Inamoto
3 papers
Zachariah DeFilipp
3 papers
Alison Sehgal
2 papers
AK
Ankit Kansagra
2 papers
Betty Hamilton
2 papers
Brian Druker
2 papers

Clinical trials

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2027
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029